Drug Discovery

#Drug discovery #Genetics / genomics #Genomics

Reproducibility in single cell genomic analysis

Listen to this article on the DDW Podcast: By Andrew Gane, Diagnostics Strategy & Technology Manager, Cytiva A cell is a base unit in biology where the genome is transcribed and translated into function. Our traditional understanding of cells rests heavily on studying cells in tissues as an identical… Read More

#Exclusive Content #News

#Covid-19 #Drug development #Drug discovery #mRNA

Can antiviral oligonucleotides better prepare us for the next pandemic?

Todd Stawicki, Global Marketing Manager for MS Biopharma at SCIEX, offers an in-depth analysis of oligonucleotides and their role in preparing for the next pandemic Covid-19, the disease caused by SARS-CoV-2, is arguably the greatest public health threat in a generation. It has temporarily paralysed our just-in-time economy1,2 and highlighted many… Read More

#Exclusive Content #News

#Drug delivery #Drug development #mRNA #Pfizer

Pfizer’s investment that will help speed up new medicine development

Around 85% of Pfizer’s small molecule products pass through Sandwich, Kent, on their journey to market. The work of the Kent site’s team helps millions of patients globally. Brian Henry, Vice President, Drug Product Design, Medicinal Sciences provides Megan Thomas, Drug Discovery World with insight into the scientific learnings of… Read More

#Exclusive Content #News

#CAR-T #Drug discovery #Immuno-oncology #Immunotherapy #Institute of Cancer Research

Immune checkpoint inhibitors: What are the risks?

Immuno-oncology has advanced greatly through T cell-based therapeutic approaches (particularly immune checkpoint inhibitors). However, immune checkpoint inhibitors (ICIs) aren’t efficacious in all patients, and they carry risks. What are these risks? Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences speaks to Lu Rahman. Preclinical in vivo models serve as important… Read More

#Cancer Research #Exclusive Content #News

#Clinical trials #Drug development #Drug discovery

163% growth in recruiting clinical trial sites in China

Virtual clinical development specialist Phesi has released its analysis of the growth in recruiting clinical trial sites in China since the beginning of 2018. The analysis finds a significant rise in the number of recruiting sites in the country, with a 163% increase between January 2018 and January 2021. While… Read More

#News

#Cancer research #CAR-T #Cell therapy #Drug development #Immuno-oncology

Innovation driving cell therapies toward the clinic

Sean Chang, Product Manager, Cell and Gene Therapy at Thermo Fisher Scientific It has been four years since the first Chimeric Antigen Receptor T-cell (CAR T) therapy drug, Kymriah1, was approved by the US Food and Drug Administration (FDA) for the treatment of B-cell acute lymphoblastic leukaemia (ALL). Since then,… Read More

#Exclusive Content #News

#Biotherapeutics #Clinical trials #Drug discovery #Life sciences

Awakn Life Sciences: new CRO and patent application

Awakn Life Sciences has appointed neuroscientist and addiction researcher, Professor David Nutt as Chief Research Officer as well as announcing the filing of patent applications in the US for two next-generation novel MDMA-derived new chemical entities. This executive appointment is driven by the expansion of Awakn’s psychedelic drug and therapy… Read More

#News

Eye
#Biotechnology #Clinical trials #Drug development #Drug discovery #Stem cells

Dry Eye Syndrome drug candidate shows promise

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More

#News

#Antibodies #Complex medicines #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug targets #Life sciences

Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More

#News

#AI #Augmented Chemistry #Data #Drug discovery #Pharma

Optibrium publishes study on AI applications in pharma

Optibrium has published a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”, working alongside Takeda Pharmaceuticals’ proprietary global dataset and the Alchemite deep learning method. The study demonstrated that deep learning generates new and valuable insights on global pharma-scale, high-value and proprietary datasets. Such datasets… Read More

#News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Sanofi launches dedicated mRNA vaccines centre

Sanofi will invest approximately €400 million annually in a vaccines mRNA Centre of Excellence. The centre will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams… Read More

#News

#Cancer research #Drug development #Drug discovery #Drug innovation #Oncology #Research #Therapeutics

Sitting down with… Mari Scheiffele, Novartis

Mari Scheiffele is the General Manager for Oncology in the UK & Ireland at Novartis, responsible for launching innovative oncology therapies that can help to change the lives of people living with different types of cancer. She speaks to Lu Rahman about her passion for working with her teams to… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Biopharmaceuticals #Drug discovery #Drug targets

Handbook for the modern antibody development process

The process of antibody discovery and development into a clinical candidate is one full of twists, turns and offshoots, yet one that an increasing number of researchers and companies, both small and large, have successfully navigated. This eBook released by Twist Biopharma is designed to be used as a… Read More

#News

#CRISPR screening #Drug discovery #Drug screening #Drug targets #Webinar

Webinar: how to achieve rapid translation of targets towards the clinic

Over recent years, interest in identifying new targets to modify an immune response to control a host of human diseases has sky-rocketed. Based in part on the success of several new immune cell targeted treatments for cancer, combined with the CRISPR-Cas revolution and the ability to culture primary immune cells… Read More

#News

#AI #Drug development #Drug discovery #Novel candidates #Therapeutics

Strategic collaboration could open the door to new world-class medicines

EQRx and Exscientia are collaborating to combine the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates and expand EQRx’s pipeline of novel therapies. This collaboration is focused on creating improvements in the traditional drug discovery and development processes by improving the probability of success… Read More

#News

#Biotherapeutics #Cancer research #CAR-T #Cell therapy #Clinical trials #Drug development

Aleta and Cancer Research UK to advance blood cancer therapy

Aleta Biotherapeutics and Cancer Research UK have collaborated to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001. Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase I/IIa clinical trial of ALETA-001,… Read More

#News